Director Sells GKOS 15,000 Shares for $1.9 Million

12 hours ago 6

Adé Hennis, The Motley Fool

Sat, January 31, 2026 astatine 4:06 PM CST 3 min read

Marc Stapley, a manager astatine Glaukos Corporation (NYSE:GKOS), executed a nonstop merchantability of 15,000 shares for a transaction worth of astir $1.9 cardinal connected Jan. 22, 2026, pursuing the workout of an equivalent fig of banal options, according to a SEC Form 4 filing.

Metric

Value

Shares sold (direct)	15,000
Transaction value	$1.92 million
Post-transaction shares (direct)	37,449
Post-transaction worth (direct ownership)	~$4.71 million

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($127.71); post-transaction worth based connected the closing terms of Jan. 22, 2026 ($125.90).

How does the size of this transaction comparison to anterior dispositions by Marc Stapley?
This merchantability of 15,000 shares materially exceeds the median administrative disposition of 6,250 shares since May 2024.
What was the structural discourse down the transaction?
The disposition resulted from a derivative event: 15,000 banal options were exercised, and the underlying shares were instantly sold, arsenic disclosed successful the filing's derivative context.
What is the broader accusation for Stapley's ownership and aboriginal capacity?
Following this transaction, nonstop holdings fell to 37,449 shares (valued astatine ~$4.71 cardinal connected the time of the transaction), representing 0.07% of outstanding shares, and with nary options outstanding.

Metric

Value

Market capitalization	$6.85 billion
Revenue (TTM)	$469.82 million
Net income (TTM)	-$87.61 million
*1-year terms change	-24.92%

* 1-year terms alteration calculated arsenic of Jan. 31, 2026.

Glaukos Corporation offers ophthalmic aesculapian devices and pharmaceutical therapies, specializing successful solutions for glaucoma and related oculus conditions. Its clients see ophthalmologists and healthcare institutions successful the United States and internationally, focusing connected patients with mild-to-moderate open-angle glaucoma and related conditions.

On Jan. 28, 2026, Glaukos announced that it received FDA support for the re-administration of 1 of its supplements to assistance glaucoma patients negociate their condition. Now, physicians tin re-administer the supplement to patients much than once, depending connected the information of their corneas. The institution continues to beryllium a ascendant unit successful a pharmaceutical marketplace that faces beardown request for products relating to oculus health.

It should besides beryllium noted that the transactions Stapley conducted were scheduled successful beforehand nether a Rule 10b5-1 trading plan, which allows an insider to acceptable up transactions for aboriginal dates.